OnDemand Cornea Update: Corneal Dystrophies and Degenerations featuring the 3rd Annual Peter & Ruth Laibson Endowed Cornea Lecture

Registration for this activity is free.

The 3rd Annual Peter & Ruth Laibson Endowed Cornea Lecture was delivered by Jayne S. Weiss, MD of LSU.

The conference begins with live patient examinations featuring patients with common and unusual corneal dystrophies and degenerations. Some patients will have been treated with laser or corneal transplant surgery including patients with recurrences of their conditions after surgery. We will then proceed with 3rd annual Laibson Endowed Cornea Lecture by invited speaker Dr. Jayne Weiss. We will conclude with presentations on corneal dystrophies and degeneration and congenital opacities, including talks on genetics and pathology.

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

1. Identify unusual corneal dystrophies, degenerations, and congenital corneal opacities.
2. Understand the genetics of corneal dystrophies.
3. Incorporate genetic analysis and consultation into patient treatment.
4. Compare currently available treatment options for specific corneal dystrophies, degenerations and congenital corneal opacities.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 2.50 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

In compliance with the Standards for Integrity and Independence in Accredited Continuing Education set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Wills Eye Hospital that the information presented at CME activities will be commercially unbiased and based upon clinical and scientific evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that all individuals in a position to control the content of a CME activity (including faculty, planners, reviewers or others) have disclosed about all financial relationships they have with ineligible companies. All relevant financial relationships have been mitigated.

Ineligible companies are companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. The CME activity staff at Wills Eye Hospital report no financial relationships with ineligible companies.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Ralph C. Eagle Jr., MD
Director
Wills Eye Hospital

Faculty

Stocks or stock options, excluding diversified mutual funds-Merck

Brenton D. Finklea, MD
Wills Eye Hospital

Faculty

Consulting Fee-Alcon

Sadeer B. Hannush, MD
Sadeer B Hannush MD

Faculty

Consulting Fee-Kowa, Inc

Aditya Kanesa-thasan, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Rebecca Procopio, MS

Faculty

Nothing to disclose

Rohini Sigireddi, MD
Wills Eye Hospital

Faculty

Nothing to disclose

Zeba A. Syed, MD
Wills Eye Hospital

Faculty

Speakers Bureau-Bio-Tissue|Advisor-Bio-Lattice|Consulting Fee-Bruder|Grant or research support-Dompé |Speakers Bureau-Tarsus|Consulting Fee-Glaukos Corporation|Consulting Fee-Recordati

jayne S weiss, MD
LSUHSC

Faculty

Nothing to disclose

Christopher J. Rapuano, MD
Wills Eye Hospital

Faculty, Planner

Consulting Fee-Sight Sciences (Relationship has ended)|Honoraria-Dompé  (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Fount Bio (Relationship has ended)|Consulting Fee-Baxis (Relationship has ended)|Consulting Fee-Emmecell (Relationship has ended)